Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...
Sepax Technologies Debuts on STAR Market with Soaring IPO Prices
Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on...
Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech
Bayer AG (ETR: BAYN) has announced market filings with the US Food and Drug Administration...
Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study
US-based Pfizer Inc. (NYSE: PFE) has reported positive topline results from its pivotal Phase III...
NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...
Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech
China-based Doma Biopharmaceutical (Suzhou) Co., Ltd has announced that it has received clearance from the...
GSK’s Shingrix Prefilled Syringe Accepted for FDA Review
UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has announced that a market filing for a prefilled syringe...
NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage
China’s National Healthcare Security Administration (NHSA) released a notification last weekend, mandating designated medical institutions...
China’s NHSA Implements New Regulations for Medical Insurance Payment Qualifications
China’s National Healthcare Security Administration (NHSA) has released the “Regulations on the Management of Medical...
Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding
Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising...
Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...
Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...
Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109
China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...
Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19
Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...
Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer
China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD)...
SynCardia’s Next-Generation Artificial Heart Granted Patent in China
US-based SynCardia Systems, LLC., a global leader in total artificial heart technology, has announced that...
Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors
On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation...
Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership...